Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
doi: 10.2147/ijwh.S282604 85 FanouriakisAKostopoulouMCheemaKAndersHJAringerMBajemaIet al
On April 21, 2026, the day after the application deadline for Medicare Part D plan sponsors to participate in the BALANCE Model, CMS announced that it would not be moving forward with implementation of the BALANCE Model in Medicare in 2027 and instead would be extending the Medicare GLP-1 Bridge to run through the end of 2027
Both disproportionality analyses confirmed this heightened risk: ROR analysis showed a statistically significant association (ROR = 1.81, 95% CI 1.622.03), while BCPNN yielded an information component of IC = 0.85 (IC025 = 0.69), both indicating substantially greater renal impairment risks in this older population treated with the combination therapy
While specific details about expanded coverage and access are still forthcoming, employers should stay informed as updates become available
Compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing
Nat Rev Neurosci (2019) 20(3):14860
US$ 29.96
US$ 25.81
US$ 21.19
US$ 25.05
US$ 24.70
US$ 29.49
US$ 29.77
US$ 21.72
US$ 29.57
US$ 29.69
US$ 22.25
